Erlotinib in advanced non-small cell lung cancer: Efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study

Journal of Thoracic Oncology

Volumn 5, Issue 10, 2010, Pages 1616-1622

  Reck, Martin ^a   Van Zandwijk, Nico ^b   Gridelli, Cesare ^c   Baliko, Zoltan ^d   Rischin, Danny ^e   Allan, Simon ^f   Krzakowski, MacIej ^g   Heigener, David ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b UNIVERSITY OF SYDNEY   (Australia)

^c S G MOSCATI HOSPITAL   (Italy)

^d Baranya County Hospital   (Hungary)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f PALMERSTON NORTH HOSPITAL   (New Zealand)

^g INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Efficacy; Erlotinib; NSCLC; Phase IV; Safety

Indexed keywords

ERLOTINIB;

ADULT; AGED; ALOPECIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD DISEASE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEPATOBILIARY DISEASE; HISTOLOGY; HUMAN; INFECTION; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MOUTH ULCER; MUSCULOSKELETAL DISEASE; NAUSEA; NUTRITIONAL DEFICIENCY; PARONYCHIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THORAX DISEASE;

EID: 77958179944     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181f1c7b0     Document Type: Article

References (21)

1. Shepherd FA, Rodrigues Pereira J, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
2. Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2006;24:3831-3837. (Pubitemid 46630729)
3. Birnbaum A, Ready N. Gefitinib therapy for non-small cell lung cancer. Curr Treat Options Oncol 2005;6:75-81. (Pubitemid 40220539)
4. Shah NT, Kris MG, Pao W, et al. Practical management of patients with non-small-cell lung cancer treated with gefitinib. J Clin Oncol 2005;23: 165-174. (Pubitemid 41702635)
5. Goodin S. Erlotinib: optimizing therapy with predictors of response? Clin Cancer Res 2006;12:2961-2963. (Pubitemid 43837338)
6. Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005;128:317-321.
7. Tsao AS, Tang XM, Sabloff B, et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006;1:231-239. (Pubitemid 47181440)
8. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361:958-967.
9. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of nonsmall-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139. (Pubitemid 38637993)
10. Van Zandwijk N, Mathy A, Boerrigter L, et al. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retroand prospective observations in non-small-cell lung cancer. Ann Oncol 2007;18:99-103. (Pubitemid 46152507)
11. Mok T, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
12. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-144. (Pubitemid 41058345)
13. Cappuzzo F, Gregorc V, Rossi E, et al. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 2003;21:2658-2663. (Pubitemid 46606308)
14. Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. Br J Cancer 2004;9: 91:208-212. (Pubitemid 39037060)
15. Clark GM. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 2008;1:406-412.
16. Clark GM, Zborowski DM, Santabarbara P, et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR. 21. Clin Lung Cancer 2006;7:389-394. (Pubitemid 44043548)
17. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-1039.
18. Murray S, Dahabreh IJ, Linardou H, et al. Somatic mutations of the tyrosine-kinase domain of epidermal growth factor receptor and tyrosine-kinase inhibitor response to TKIs in non-small-cell lung cancer: an analytical database. J Thorac Oncol 2008;3:832-839.
19. Brugger W, Triller N, Blasinska-Morawiec M, et al. Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. J Clin Oncol 2009;27(Suppl 15):411s(Abstract 8020).
20. Cappuzzo F, Coudert B, Wierzbicki R, et al. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. J Thorac Oncol 2009;4(Suppl 1):S289 (Abstract A2.1).
21. Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3922. (Pubitemid 47037599)